JP2023525720A5 - - Google Patents
Info
- Publication number
- JP2023525720A5 JP2023525720A5 JP2022567469A JP2022567469A JP2023525720A5 JP 2023525720 A5 JP2023525720 A5 JP 2023525720A5 JP 2022567469 A JP2022567469 A JP 2022567469A JP 2022567469 A JP2022567469 A JP 2022567469A JP 2023525720 A5 JP2023525720 A5 JP 2023525720A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- receptor
- domain
- antigen
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063023191P | 2020-05-11 | 2020-05-11 | |
| US63/023,191 | 2020-05-11 | ||
| US202063133224P | 2020-12-31 | 2020-12-31 | |
| US63/133,224 | 2020-12-31 | ||
| PCT/US2021/031878 WO2021231505A1 (en) | 2020-05-11 | 2021-05-11 | Vectors and methods for in vivo transduction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023525720A JP2023525720A (ja) | 2023-06-19 |
| JP2023525720A5 true JP2023525720A5 (https=) | 2024-05-17 |
Family
ID=78524914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567469A Pending JP2023525720A (ja) | 2020-05-11 | 2021-05-11 | Ｉｎ ｖｉｖｏ形質導入のためのベクター及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230304031A1 (https=) |
| EP (1) | EP4149495A4 (https=) |
| JP (1) | JP2023525720A (https=) |
| KR (1) | KR20230010231A (https=) |
| CN (1) | CN115968300A (https=) |
| AU (1) | AU2021273253A1 (https=) |
| CA (1) | CA3176697A1 (https=) |
| IL (1) | IL297514A (https=) |
| WO (1) | WO2021231505A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| WO2020191233A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN116178567B (zh) * | 2022-10-28 | 2025-01-28 | 四川大学华西医院 | 一种靶向TGFβRII的嵌合抗原受体及其用途 |
| EP4724461A1 (en) * | 2023-06-07 | 2026-04-15 | The Broad Institute, Inc. | Engineered viral like particles (evlps) for the selective transduction of target cells |
| WO2025033948A1 (ko) * | 2023-08-07 | 2025-02-13 | 마루테라퓨틱스 주식회사 | 유전자 고효율 발현이 가능한 비바이러스성 듀얼 플라스미드 벡터와 이를 발현하는 줄기세포 및 분화된 조혈계 세포 |
| CN116814664B (zh) * | 2023-08-25 | 2023-12-12 | 中国医学科学院肿瘤医院 | 一种扩展肿瘤识别表位的cea嵌合抗原受体t细胞的制备与应用 |
| CN116814595B (zh) * | 2023-08-30 | 2023-11-28 | 江苏申基生物科技有限公司 | 一种腺苷脱氨酶突变体及其固定化 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681746A (en) * | 1994-12-30 | 1997-10-28 | Chiron Viagene, Inc. | Retroviral delivery of full length factor VIII |
| US7001733B1 (en) * | 1998-05-12 | 2006-02-21 | Rigel Pharmaceuticals, Inc. | Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement |
| US8383124B2 (en) * | 2008-03-12 | 2013-02-26 | Children's Hospital Medical Center | Mobilization of hematopoietic stem cells |
| CN102099472A (zh) * | 2008-05-19 | 2011-06-15 | 新加坡科技研究局 | 使基因表达靶向于神经胶质瘤的核酸分子和方法 |
| EP2294218A2 (en) * | 2008-06-02 | 2011-03-16 | New York University | Compositions and methods for diagnosis, prognosis and treatment of mesothelioma |
| US20110020814A1 (en) * | 2009-06-05 | 2011-01-27 | Ipierian, Inc. | Methods and compositions for selection of stem cells |
| JP5923037B2 (ja) * | 2009-06-17 | 2016-05-24 | トカジェン インコーポレーテッド | 複製可能レトロウイルスベクターの産生細胞 |
| US9839696B2 (en) * | 2010-04-30 | 2017-12-12 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| US9642921B2 (en) * | 2012-12-20 | 2017-05-09 | Tocagen Inc. | Cancer combination therapy and recombinant vectors |
| CA3051222C (en) * | 2013-06-10 | 2023-01-24 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for reducing immunosupression by tumor cells |
| WO2015021077A1 (en) * | 2013-08-05 | 2015-02-12 | Tocagen Inc. | Recombinant vector with optimized a-bulge |
| HRP20191873T1 (hr) * | 2014-12-12 | 2020-01-24 | Bluebird Bio, Inc. | Kimerni antigenski receptori |
| JP2018526007A (ja) * | 2015-09-04 | 2018-09-13 | トカジェン インコーポレーテッド | ２ａペプチドを含む組換えベクター |
| US11111505B2 (en) * | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| CU24649B1 (es) * | 2016-03-19 | 2023-02-13 | Exuma Biotech Corp | Retrovirus recombinantes incompetentes de replicación para la transducción de linfocitos y expansión regulada de los mismos |
| CA3030003A1 (en) * | 2016-07-08 | 2018-01-11 | F1 Oncology, Inc. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| IL270028B2 (en) * | 2017-04-21 | 2025-10-01 | Ospedale San Raffaele Srl | Garden care |
| US20180327857A1 (en) * | 2017-05-09 | 2018-11-15 | Shanghai Realgen Biotech Co., Ltd. | Diagnostic biomarker and diagnostic method |
| US20210130775A1 (en) * | 2017-08-02 | 2021-05-06 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed |
| US20210213119A1 (en) * | 2018-08-28 | 2021-07-15 | Immunotech Biopharm Co., Ltd. | Improved therapeutic t cell |
-
2021
- 2021-05-11 KR KR1020227043191A patent/KR20230010231A/ko active Pending
- 2021-05-11 WO PCT/US2021/031878 patent/WO2021231505A1/en not_active Ceased
- 2021-05-11 JP JP2022567469A patent/JP2023525720A/ja active Pending
- 2021-05-11 CN CN202180048754.2A patent/CN115968300A/zh active Pending
- 2021-05-11 CA CA3176697A patent/CA3176697A1/en active Pending
- 2021-05-11 EP EP21803598.8A patent/EP4149495A4/en not_active Withdrawn
- 2021-05-11 US US17/924,080 patent/US20230304031A1/en active Pending
- 2021-05-11 AU AU2021273253A patent/AU2021273253A1/en not_active Abandoned
- 2021-05-11 IL IL297514A patent/IL297514A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023525720A5 (https=) | ||
| IL297514A (en) | Vectors and methods for in vivo transduction | |
| JP2023518049A5 (https=) | ||
| JP2021525509A5 (https=) | ||
| JP2024518011A5 (https=) | ||
| JP2020500530A5 (https=) | ||
| IL297547A (en) | Therapeutic interventional particles for the corona virus | |
| JP2019525956A5 (https=) | ||
| JP2025037871A5 (https=) | ||
| JP2019518424A5 (https=) | ||
| JP2017513818A5 (https=) | ||
| JP2023516008A5 (https=) | ||
| JP2025078629A5 (https=) | ||
| RU2019133286A (ru) | Биомаркеры и средства терапии на основе т-клеток с car с повышенной эффективностью | |
| US20230028399A1 (en) | Bcma-directed cellular immunotherapy compositions and methods | |
| HRP20230457T1 (hr) | Pripravci i postupci za selektivnu ekspresiju kimernih antigenskih receptora | |
| JP2023529211A5 (https=) | ||
| JP2019500394A5 (https=) | ||
| JP2021532742A5 (https=) | ||
| US20220152101A1 (en) | Cellular immunotherapy combination | |
| JP2024510900A5 (https=) | ||
| CA3224478A1 (en) | Bcma-directed cellular immunotherapy compositions and methods | |
| CN110468105A (zh) | 表达il-18r结合蛋白的免疫效应细胞 | |
| WO2023207390A1 (zh) | 一种ciita基因被敲除的工程化免疫细胞及其用途 | |
| JP2022516710A5 (https=) |